Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1259257.RAaCziJSylVcShen-81YdrtLGRfpqdk1LapEQ1xKwlbew130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1259257.RAaCziJSylVcShen-81YdrtLGRfpqdk1LapEQ1xKwlbew130_assertion type Assertion NP1259257.RAaCziJSylVcShen-81YdrtLGRfpqdk1LapEQ1xKwlbew130_head.
- NP1259257.RAaCziJSylVcShen-81YdrtLGRfpqdk1LapEQ1xKwlbew130_assertion description "[BCR signaling pathway inhibitors such as ibrutinib, idelalisib, and fostamatinib (respective inhibitors of Bruton's tyrosine kinase, PI3K?, and spleen tyrosine kinase) represent a significant therapeutic advance in B cell malignancies, including chronic lymphocytic leukemia (CLL).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1259257.RAaCziJSylVcShen-81YdrtLGRfpqdk1LapEQ1xKwlbew130_provenance.
- NP1259257.RAaCziJSylVcShen-81YdrtLGRfpqdk1LapEQ1xKwlbew130_assertion evidence source_evidence_literature NP1259257.RAaCziJSylVcShen-81YdrtLGRfpqdk1LapEQ1xKwlbew130_provenance.
- NP1259257.RAaCziJSylVcShen-81YdrtLGRfpqdk1LapEQ1xKwlbew130_assertion SIO_000772 25632006 NP1259257.RAaCziJSylVcShen-81YdrtLGRfpqdk1LapEQ1xKwlbew130_provenance.
- NP1259257.RAaCziJSylVcShen-81YdrtLGRfpqdk1LapEQ1xKwlbew130_assertion wasDerivedFrom befree-2016 NP1259257.RAaCziJSylVcShen-81YdrtLGRfpqdk1LapEQ1xKwlbew130_provenance.
- NP1259257.RAaCziJSylVcShen-81YdrtLGRfpqdk1LapEQ1xKwlbew130_assertion wasGeneratedBy ECO_0000203 NP1259257.RAaCziJSylVcShen-81YdrtLGRfpqdk1LapEQ1xKwlbew130_provenance.